Royal Bank of Canada’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.3M | Buy |
111,543
+2,747
| +3% | +$543K | ﹤0.01% | 1378 |
|
|
2025
Q4 | $20.6M | Buy |
108,796
+5,303
| +5% | +$1.02M | ﹤0.01% | 1486 |
|
|
2025
Q3 | $18.3M | Buy |
103,493
+94,033
| +994% | +$14M | ﹤0.01% | 1718 |
|
|
2025
Q2 | $1.07M | Buy |
9,460
+3,340
| +55% | +$357K | ﹤0.01% | 3834 |
|
|
2025
Q1 | $644K | Buy |
6,120
+1,256
| +26% | +$142K | ﹤0.01% | 3805 |
|
|
2024
Q4 | $521K | Buy |
4,864
+734
| +18% | +$83K | ﹤0.01% | 4063 |
|
|
2024
Q3 | $414K | Buy |
4,130
+591
| +17% | +$59.5K | ﹤0.01% | 4239 |
|
|
2024
Q2 | $298K | Buy |
3,539
+1,254
| +55% | +$99.8K | ﹤0.01% | 4430 |
|
|
2024
Q1 | $167K | Sell |
2,285
-4,703
| -67% | -$347K | ﹤0.01% | 4837 |
|
|
2023
Q4 | $498K | Buy |
6,988
+1,711
| +32% | +$101K | ﹤0.01% | 4264 |
|
|
2023
Q3 | $316K | Buy |
5,277
+301
| +6% | +$19.8K | ﹤0.01% | 4404 |
|
|
2023
Q2 | $360K | Buy |
4,976
+2,015
| +68% | +$151K | ﹤0.01% | 4207 |
|
|
2023
Q1 | $218K | Sell |
2,961
-2,010
| -40% | -$143K | ﹤0.01% | 4547 |
|
|
2022
Q4 | $333K | Buy |
4,971
+1,582
| +47% | +$103K | ﹤0.01% | 4448 |
|
|
2022
Q3 | $183K | Buy |
3,389
+374
| +12% | +$22K | ﹤0.01% | 4843 |
|
|
2022
Q2 | $168K | Sell |
3,015
-1,340
| -31% | -$76K | ﹤0.01% | 4933 |
|
|
2022
Q1 | $306K | Sell |
4,355
-4,123
| -49% | -$299K | ﹤0.01% | 4694 |
|
|
2021
Q4 | $817K | Buy |
8,478
+1,834
| +28% | +$169K | ﹤0.01% | 4021 |
|
|
2021
Q3 | $578K | Sell |
6,644
-28,856
| -81% | -$2.23M | ﹤0.01% | 4219 |
|
|
2021
Q2 | $2.9M | Buy |
35,500
+3,071
| +9% | +$255K | ﹤0.01% | 2740 |
|
|
2021
Q1 | $3.08M | Sell |
32,429
-15,565
| -32% | -$1.47M | ﹤0.01% | 2644 |
|
|
2020
Q4 | $2.98M | Sell |
47,994
-2,103
| -4% | -$120K | ﹤0.01% | 2574 |
|
|
2020
Q3 | $2.98M | Buy |
50,097
+59
| +0.1% | +$4.03K | ﹤0.01% | 2370 |
|
|
2020
Q2 | $3.49M | Buy |
50,038
+3,976
| +9% | +$252K | ﹤0.01% | 2199 |
|
|
2020
Q1 | $2.09M | Buy |
46,062
+1,200
| +3% | +$68K | ﹤0.01% | 2435 |
|
|
2019
Q4 | $2.92M | Sell |
44,862
-35,009
| -44% | -$2.34M | ﹤0.01% | 2552 |
|
|
2019
Q3 | $4.96M | Sell |
79,871
-60,040
| -43% | -$3.77M | ﹤0.01% | 2091 |
|
|
2019
Q2 | $9.96M | Buy |
139,911
+42,274
| +43% | +$3.11M | ﹤0.01% | 1564 |
|
|
2019
Q1 | $7.66M | Sell |
97,637
-279
| -0.3% | -$21.1K | ﹤0.01% | 1700 |
|
|
2018
Q4 | $8.29M | Buy |
97,916
+50,039
| +105% | +$5.33M | ﹤0.01% | 1624 |
|
|
2018
Q3 | $8.2M | Sell |
47,877
-69,883
| -59% | -$10.5M | ﹤0.01% | 1741 |
|
|
2018
Q2 | $15.2M | Sell |
117,760
-44,832
| -28% | -$5M | 0.01% | 1250 |
|
|
2018
Q1 | $16.8M | Sell |
162,592
-8,974
| -5% | -$887K | 0.01% | 1210 |
|
|
2017
Q4 | $14.7M | Buy |
171,566
+14,230
| +9% | +$1.23M | 0.01% | 1344 |
|
|
2017
Q3 | $13.4M | Sell |
157,336
-111,877
| -42% | -$8.86M | 0.01% | 1344 |
|
|
2017
Q2 | $20.4M | Buy |
269,213
+123,972
| +85% | +$8.67M | 0.01% | 1044 |
|
|
2017
Q1 | $9.59M | Buy |
145,241
+122,547
| +540% | +$8.06M | 0.01% | 1510 |
|
|
2016
Q4 | $1.44M | Sell |
22,694
-7,986
| -26% | -$504K | ﹤0.01% | 2841 |
|
|
2016
Q3 | $1.95M | Sell |
30,680
-14,335
| -32% | -$1.05M | ﹤0.01% | 2572 |
|
|
2016
Q2 | $3.35M | Buy |
45,015
+18,790
| +72% | +$1.39M | ﹤0.01% | 2152 |
|
|
2016
Q1 | $1.75M | Buy |
26,225
+16,886
| +181% | +$1.03M | ﹤0.01% | 2585 |
|
|
2015
Q4 | $632K | Buy |
9,339
+341
| +4% | +$21.1K | ﹤0.01% | 3540 |
|
|
2015
Q3 | $481K | Buy |
8,998
+1,693
| +23% | +$103K | ﹤0.01% | 3551 |
|
|
2015
Q2 | $460K | Sell |
7,305
-295
| -4% | -$16.1K | ﹤0.01% | 3681 |
|
|
2015
Q1 | $366K | Buy |
+7,600
| New | +$291K | ﹤0.01% | 3782 |
|
|
2014
Q2 | – | Sell |
-66
| Closed | -$3K | – | 6047 |
|
|
2014
Q1 | $3K | Sell |
66
-861
| -93% | -$35.9K | ﹤0.01% | 5670 |
|
|
2013
Q4 | $30K | Buy |
927
+719
| +346% | +$23.4K | ﹤0.01% | 5099 |
|
|
2013
Q3 | $6K | Sell |
208
-581
| -74% | -$16.3K | ﹤0.01% | 5582 |
|
|
2013
Q2 | $19K | Buy |
+789
| New | +$14.2K | ﹤0.01% | 5044 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Royal Bank of Canada's LGND Position: Q1 2026 in Review
Royal Bank of Canada increased its Ligand Pharmaceuticals (LGND) stake by 2.5% in Q1 2026, buying an estimated $543K and bringing the position to 111,543 shares worth $22.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1378.
Royal Bank of Canada first reported a position in LGND in Q2 2013 and has held it in 49 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Royal Bank of Canada held 111,543 shares of Ligand Pharmaceuticals worth $22.3M as of Q1 2026.
- Royal Bank of Canada bought 2,747 Ligand Pharmaceuticals shares in Q1 2026, an estimated $543K.
- Ligand Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1378 holding.
- Royal Bank of Canada first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.